Thu Sep 12 20:36:00 UTC 2024: ## New Treatments on the Horizon for Lupus: A Shifting Landscape
**EXTON, PA – September 12, 2024** – The treatment landscape for systemic lupus erythematosus (SLE) is undergoing a significant transformation with multiple new therapies entering the market, offering hope for patients suffering from this chronic and debilitating disease.
According to a recent report by Spherix Global Insights, Biogen’s litifilimab stands out as a promising contender, demonstrating superior efficacy in Phase II trials compared to existing biologics like Benlysta (GSK) and Saphnelo (AstraZeneca).
Other potential game-changers include AbbVie’s Rinvoq (upadacitinib) and Bristol Myers Squibb’s Sotyktu (deucravacitinib). While these oral therapies offer convenience for patients, potential challenges include adherence and concerns related to the black box warning associated with JAK inhibitors.
Rheumatologists, however, are enthusiastic about the potential of these new treatments, particularly for skin manifestations. Rinvoq, Sotyktu, and litifilimab are seen as having the strongest potential in this area.
Despite the emergence of these new treatments, Benlysta continues to hold a dominant position in the market, particularly for lupus nephritis. Its well-established safety profile and familiarity among healthcare providers have solidified its place in the lupus treatment landscape.
Other therapies have carved out niche roles: Saphnelo (AstraZeneca) is preferred for chronic cutaneous lupus erythematosus (CCLE) and Lupkynis (Aurinia) is the top choice for patients with high, persistent proteinuria.
The arrival of these new treatments will bring much-needed diversity to the SLE treatment options. However, they face a significant challenge: they need to demonstrate not only strong efficacy but also a compelling safety profile, ease of administration, and long-term benefits to compete with established therapies like Benlysta and other emerging treatments.
First Piper 